Armed with European approval for its new diabetes treatment Victoza, Novo Nordisk plans a launch this summer in Britain, Germany and Denmark, with other European markets to follow. The company is still awaiting FDA's blessing after thyroid safety questions prompted questions from an expert advisory panel. Report